Unraveling the Complexity of Endocrine Resistance in Breast Cancer by Functional Genomics
Cancer CellPublished 1 February 2008Open access
Charles Swanton, Julian Downward
Citations11
SJR quartileQ1
SJR score19.03
SNIP5.73
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
CDK10 loss increases the activity of the transcription factor ETS2 on the promoter of the RAF1 gene, elevating ERK/MAPK kinase pathway activity and relieving tamoxifen-induced G1 arrest, and is a potential biomarker for sensitivity in prospective clinical trials of patients treated with endocrine therapies.
Abstract
Despite the proven benefit of antiestrogen drugs in breast cancer treatment, resistant disease ultimately develops in advanced breast cancer. In this issue of Cancer Cell, Iorns et al. find that loss of CDK10 expression promotes resistance of cells to tamoxifen and is associated with poor outcome in breast cancer patients treated with the drug. CDK10 loss increases the activity of the transcription factor ETS2 on the promoter of the RAF1 gene, elevating ERK/MAPK kinase pathway activity and relieving tamoxifen-induced G1 arrest. CDK10 is thus a potential biomarker for sensitivity in prospective clinical trials of patients treated with endocrine therapies.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
The LancetEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
7,563 Citations2005
The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.
Journal of Biological ChemistryCyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
1,223 Citations1996Josée N. Lavoie, Gilles L’Allemain +3 more
The notion that MAPK cascades drive specific cell cycle responses to extracellular stimuli, at least in part, through the modulation of cyclin D1 expression and associated cdk activities is supported.
NatureOpposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence
635 Citations2001Naoko Ohtani, Zoë Zebedee +7 more
A role is demonstrated for the Ets1 and Ets2 transcription factors based on their ability to activate the p16INK4a promoter through an ETS-binding site and their patterns of expression during the lifespan of human diploid fibroblasts.
Molecular and Cellular BiologyACTR/AIB1 Functions as an E2F1 Coactivator To Promote Breast Cancer Cell Proliferation and Antiestrogen Resistance
262 Citations2004Maggie C. Louie, June X. Zou +2 more
It is shown that overexpression of ACTR not only enhances estrogen-stimulated cell proliferation but also, more strikingly, completely negates the cell cycle arrest effect by tamoxifen and pure antiestrogens.
OncogeneCdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity
114 Citations2001Margaret M. Kasten, Antonio Giordano
It is reported that Cdk10 interacts with the N-terminus of the Ets2 transcription factor, which contains the highly conserved Pointed domain and transactivation domain, and binds full length ETS2 in vitro and in vivo and inhibits Ets1 transactivation in mammalian cells.
OncogeneERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis
112 Citations2005Sofie Svensson, Karin Jirström +5 more
Interestingly, ERK1/2 phosphorylation correlated with better survival in untreated patients independently of lymph-node status and tumour size indicating that ERK 1/2 signalling might be associated with a less aggressive phenotype.
Molecular and Cellular BiologyBiallelic Mutations in p16<sup>INK4a</sup> Confer Resistance to Ras- and Ets-Induced Senescence in Human Diploid Fibroblasts
104 Citations2002Thomas J. G. Huot, Janice Rowe +10 more
The data imply that INK4a assumes this role in human fibroblasts, as indicated by the fact that in relatively young Q34 cells anchorage independence can be achieved without addition of telomerase or perturbation of the p53 pathway.
Journal of Biological ChemistryThe Raf-1/MEK/ERK Pathway Regulates the Expression of the p21Cip1/Waf1 Gene in Chondrocytes
90 Citations1999Frank Beier, Allison C. Taylor +1 more
It is suggested that signaling through the Raf-1 pathway is necessary for the optimal expression of p21 in chondrocytes and may play an important role in the control of bone formation.
The ProstateRaf‐1 expression may influence progression to androgen insensitive prostate cancer
47 Citations2005R Mukherjee, John M.S. Bartlett +3 more
This work has reported gene amplification of critical members of the MAP kinase pathway with the development of androgen insensitive prostate cancer (AIPC) and confirmed the role of EMT in this disease.
PLoS ONEFunctional Ablation of pRb Activates Cdk2 and Causes Antiestrogen Resistance in Human Breast Cancer Cells
30 Citations2007Hemant Varma, Andrew Skildum +1 more
It is demonstrated that antiestrogens do not inhibit cdk2 activity or proliferation of MCF-7 cells in the absence of pRb family function, and suggest thatAntiestrogen resistant breast cancer cells resulting from pRB pathway inactivation would be susceptible to therapies that target cdk 2.
CancerEnhancing endocrine response with novel targeted therapies
16 Citations2007Stephen Johnston, Alexandra Léary +3 more
By applying more rigorous trial design and tumor selection criteria to future trials, it is much more likely that adding the new generation of targeted therapies can fulfill its promise in enhancing endocrine responsiveness and the authors' ability to treat breast cancer patients.